https://www.bioworld.com/articles/500353-other-new
Post# of 36563
(Total Views: 410)
Posted On: 11/18/2020 11:46:07 PM
https://www.bioworld.com/articles/500353-othe...ov-18-2020
Generex Biotechnology Corp., of Miramar, Fla., said it closed a licensing and development agreement with a consortium of partners in China covering the Ii-Key vaccine platform technology from its subsidiary, Nugenerex Immuno-Oncology. Generex is set to receive a licensing fee of up to $50 million for exclusive use of the Ii-Key platform for infectious disease and cancer in China and its territories. For each product developed using the technology under the platform license, Generex will receive an up-front payment; full funding of product development, regulatory approval and commercialization in China; a milestone payment upon product approval; and a royalty to be determined on a case-by-case basis. The agreement incorporated the first Ii-Key platform project, development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China, calling for a $5 million up-front licensing fee; full funding for manufacturing, development and commercial registration; $20 million upon approval of a Ii-Key-SARS-CoV-2 vaccine in China; and royalty payments for COVID-19 vaccine sales in China with the potential to reach several billion dollars. The agreement included provisions to advance the development of Ii-Key vaccines for infectious diseases and cancer under separate contracts.
Generex Biotechnology Corp., of Miramar, Fla., said it closed a licensing and development agreement with a consortium of partners in China covering the Ii-Key vaccine platform technology from its subsidiary, Nugenerex Immuno-Oncology. Generex is set to receive a licensing fee of up to $50 million for exclusive use of the Ii-Key platform for infectious disease and cancer in China and its territories. For each product developed using the technology under the platform license, Generex will receive an up-front payment; full funding of product development, regulatory approval and commercialization in China; a milestone payment upon product approval; and a royalty to be determined on a case-by-case basis. The agreement incorporated the first Ii-Key platform project, development and commercialization of the Ii-Key-SARS-CoV-2 coronavirus vaccine in China, calling for a $5 million up-front licensing fee; full funding for manufacturing, development and commercial registration; $20 million upon approval of a Ii-Key-SARS-CoV-2 vaccine in China; and royalty payments for COVID-19 vaccine sales in China with the potential to reach several billion dollars. The agreement included provisions to advance the development of Ii-Key vaccines for infectious diseases and cancer under separate contracts.
(2)
(0)